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Abstract This study investigates the potential role of 17 chosen polymorphisms in
15 candidate genes and the risk of myocardial infarction in patients under 45 years
of age. The study consists of 271 patients with myocardial infarction and 141
controls. The analysis of genetic polymorphisms was performed using the PCR–
RFLP method. Of the chosen polymorphisms, two (Leu125Val PECAM1 and A1/
A2 FVII) are related to myocardial infarction and two (C677T MTHFR and 5A/6A
MMP3) to advanced stenosis in arterial vessels ([ 75%). We also found that the
frequency of some combinations among the analyzed genes and environmental
factors varied between the patient and control groups.
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Introduction
Vascular diseases, including coronary artery disease, are the leading cause of death
in developed countries. The data indicate that persons under 45 years of age
constitute approximately 10% of all patients with myocardial infarction (Doughty
et al. 2002). Among young people, the leading factor for myocardial infarction
(besides the classic risk factors of hypercholesterolemia, arterial hypertension,
smoking, and diabetes mellitus) is a positive family history among first-degree
relatives (Garoufalis et al. 1998; Sakowicz et al. 2010b), perhaps because
environmental factors have had less time to exert a dominating influence on the
disease process in young people (Chaer et al. 2004).
Approximately 90% of all cases of myocardial infarction are the result of acute
thrombus, causing obstruction of an artery vessel in places of atherosclerosis plaque
rupture (Sakowicz et al. 2010b). The etiopathogenesis of atherosclerosis plaque is
still not clear. Several theories or hypotheses about atherogenesis have been
proposed. The most probable is the unified theory in which atherosclerosis is caused
by complicated interactions among cells of the endothelium, blood cells, and
lipoprotein. Damage to the endothelium leads to its dysfunction and activation
(Libby 2002). This activation is related to the increased expression of chemoattrac-
tant cytokines, lecithin-like oxidized low-density lipoprotein receptor-1 (LOX-1),
and adhesion molecules such as selectin E, intracellular adhesion molecule type 1
(ICAM1), vascular adhesion molecule (VCAM), and platelet endothelial cell
adhesion molecule type 1 (PECAM1) (Libby 2002). These molecules help
leukocytes adhere to the endothelium and migrate into the intima layer of the
artery. This process increases inflammation in the vessel. Lymphocytes, macro-
phages, and other cells (e.g., smooth muscle cells) secrete many different cytokines,
metalloproteinases, and factors involved in the progression and disruption of the
lesion (Libby 2002). The matrix metalloproteins MMP1, MMP2, MMP3, and MMP9
are involved in degradation of the extracellular matrix, weakening the fibrous cap
and subsequently destabilizing atherosclerotic lesions (Koenig and Khuseyinova
2007; Ye 2006). The fibrous cap overlies the athermanous lipid core. The disruption
of the atherosclerotic plaque exposes the procoagulants (e.g., phospholipids, tissue
factor or platelet-adhesive matrix molecules) that accumulate in the lipid core to
blood, which triggers thrombosis (Libby 2002, 2008). It has been hypothesized that
impaired fibrinolytic function may also be a risk factor for ischemic events (Morange
et al. 2006).
The purpose of this study was to identify which of 17 polymorphisms [C677T
MTHFR (rs1801133), Ser128Arg Selectin E (rs5361), K469E ICAM1 (rs5030382),
Leu125Val PECAM1 (rs71647806), Ser563Asn PECAM1 (rs1135028), K167N
LOX1 (rs11053646), –16071G/2G MMP1 (rs17886084), –16125A/6A MMP3
(rs3025058), –1562C/T MMP9 (rs3918242), –603A/G TF (rs1361600), G1691A
FV (rs6025), –6754G/5G PAI1 (rs34857375), –148C/T fibrinogen (rs1800787),
–455G/A fibrinogen (rs1800790), –323A1/A2 FVII, R353Q FVII (rs 6046), IVS7
FVII (H5, H6, H7, H8)] promote susceptibility to myocardial infarction in patients
under 45 years of age.




Blood samples were collected from 272 unrelated patients in whom a first incident
of myocardial infarction occurred before 45 years of age. All subjects were white
Caucasians and showed no typical symptoms of coronary artery disease before the
first incident. Myocardial infarction was confirmed by chest pain associated with
specific ischemic ECG changes, high serum troponin (T or I), and increased CKMB
activity. The participants reported having undergone coronary angiography during
their first hospitalization to determine the level of atherosclerotic lesion progression.
The coronary segments (right coronary artery: proximal, middle, distal; main left
coronary artery: left anterior descending artery, two segments of diagonal branches,
left circumflex artery, and marginal branches) identified visually as abnormal were
measured quantitatively. Coronary stenoses were scored as significant in the case of
a mean lumen diameter reduction of 75% of a stenosed vessel.
The control group consisted of 141 unrelated, asymptomatic, apparently healthy
subjects. The inclusion criteria for the control group were age over 45 years
(confirming that the subject did not suffer from myocardial infarction before the age
of 45) and no symptoms of coronary artery disease. All participants without
symptoms of coronary artery disease were recruited from the same geographic
region as the patients and were selected randomly.
High blood pressure, hypercholesterolemia (elevated total serum cholesterol
levels [ 200 mg/dl), and the habit of smoking were not exclusion criteria for the
control or patient groups. All information about patients covered the period of time
before the first incident of myocardial infarction. We also collected information
about positive myocardial infarction or coronary artery disease for first-degree
relatives. Patients and controls with diabetes mellitus were not enrolled in the study.
The most important criterion for participation in the control or patient groups,
besides coronary artery disease, was age. We considered the year and the month of
birth in determining age; for example, if a myocardial infarction occurred in the
calendar year of a subject’s 45th birthday, but in the month before that birthday, the
person was qualified in the study group and registered in the database as 45 years
old.
The Institutional Ethics Committee of the Medical University of Lodz has
approved the study protocol and sample size. All participants were obliged to sign
an informed consent form before enrollment in the study.
Genotype Determination
Venous blood from all individuals in the study was collected in vials containing
3.2% sodium citrate. Samples were stored frozen at –20C until extraction of DNA.
Genomic DNA was extracted from blood leukocytes using standard methods
(phenol–chloroform).
Genomic DNA template samples of 100 ng and 50 pM of each primer (Table 1)
were used in the polymerase chain reaction (PCR). Denaturation was performed at
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94C for 60 s, annealing at 55–60C for 60 s, and extension at 72C for 45 s, in 30
cycles of amplification. DNA amplification was followed by restriction enzyme
digestion and polyacrylamide gel electrophoresis (RFLP).
Statistical Analysis
Age was expressed as median and interquartile range due to a non-normal
distribution. The frequency of alleles was tested against Hardy–Weinberg equilib-
rium. Pearson chi-square, Yates corrected chi-square, or two-tailed Fisher exact
tests were used for data comparisons, depending on the number of cases. Logistic
Table 2 Characteristics of study participants
Characteristic Patients (272) Controls (141) p
Age in years 40 ± 4.9 54 ± 8.6 \0.0001
Male (%) 222 (82) 67 (48) \0.0001
Smoker (%) 170 (62) 83 (59) \0.55
Arterial hypertension (%) 112 (41) 20 (14) \0.00001
Hypercholesterolemia (%) 169 (59) 49 (35) \0.00001
First-degree relative with myocardial infarction (%) 121 (44) 43 (30) \0.008
Table 3 Frequency of polymorphic alleles among myocardial infarction patients under 45
Polymorphism Controls (%) Patients (%) p
MTHFR C667T 35.46 41.18 0.31
PECAM1 L125V 51.06 69.49 0.0004
PECAM1 G1688A 66.66 70.48 0.15
Selectin E Ser128Arg 24.11 26.47 0.49
ICAM1 K469E 62.41 66.91 0.42
MMP1 (-1607 1G/2G) 68.09 47.06 0.41
MMP9 (-1562 C/T) 17.02 28.31 0.02
MMP3 (-1612 5A/6A) 39.01 44.12 0.52
LOX-1 K167N 14.89 15.81 0.92
TF (-603 A/G) 49.65 52.94 0.59
PAI (-675 4G/5G) 65.96 66.18 0.95
Fibrinogen HindIII (-146 C/T) 56.03 57.72 0.82
Fibrinogen HaeIII (-455 G/A) 57.45 56.25 0.90
FV 1691 G/A 9.22 5.88 0.29
FVII (-323 A1/A2) 24.11 15.81 0.055
FVII R353Q 24.11 18.75 0.25
FVII IVS7 (H5/H6/H7/H8) 56.03 49.26 0.23
Biochem Genet (2013) 51:230–242 235
123
regression analysis was performed to determine the association of particular factors
with the incidence of a myocardial infarction before 45 years of age. Univariate
comparisons were performed for all analyzed factors, and factors with p values
\ 0.15 were entered into a multivariate backward, stepwise model. A final p value
Table 4 Association of myocardial infarction with clinical and genetic factors in patients under 45 years
of age
Factor Multivariate logistic regression
OR 95% CI
Male 2.604 1.952 3.473
Carrier G PECAM1 (C373G, Leu125Val) 1.571 1.185 2.082
Carrier A2 FVII (A1/A2) 0.674 0.482 0.943
Hypertension 1.816 1.290 2.557
Hypercholesterolemia 1.460 1.123 1.897
First-degree relative with myocardial infarction 1.581 1.174 2.128
Carrier T MMP9 and hypertension 1.539 1.129 2.099
Carrier A PECAM1 (G1688A, Ser563Asn) and
first-degree relative with myocardial infarction
1.756 1.256 2.455
Table 5 Percentage of minor-allele carriers with critical stenosis
Minor allele Number of coronary arteries with stenosis [75% p
0 (%) 1 (%) 2 (%) 3 (%)
MTHFR 667T 38.55 34.78 47.50 61.76 0.03
PECAM1 125V 62.65 72.17 77.50 67.65 0.32
PECAM1 1688A 32.53 30.70 30.00 17.65 0.43
Selectin E 128Arg 25.30 28.70 25.00 23.53 0.91
ICAM1 469E 71.08 71.30 55.00 55.88 0.11
MMP1 –1607 2G 57.83 41.74 37.50 50.00 0.08
MMP9 –1562 T 30.12 27.83 25.00 29.41 0.94
MMP3 –1612 6A 95.18 93.91 92.50 97.06 0.07
LOX-1 167N 19.28 10.43 25.00 14.71 0.12
TF –603G 49.40 50.43 62.50 58.82 0.44
PAI –675 5G 80.72 55.65 70.00 61.76 0.003
Fibrinogen –148C/T 59.04 57.39 52.50 61.76 0.86
Fibrinogen –455G/A 60.24 54.78 50.00 58.82 0.71
FV 1691 A 9.64 4.35 2.50 5.88 0.33
FVII –323A2 20.48 14.78 12.50 11.76 0.53
FVII 353 Q 21.69 16.52 20.00 17.65 0.82
FVII H7 54.22 47.83 35.00 58.82 0.14
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below 0.05 was deemed statistically significant in the multivariate analysis.
Statistica 8.0 and Medcalc 9.36 statistical packages were used for all computations.
Results
Of the 413 participants in the study (70% of whom were male), 141 formed the
control group (48% male), and 272 constituted the study group (82% male)
(Table 2). The clinical factors of hypertension, hypercholesterolemia, and smoking
were more frequently observed in the study group than in the controls. The patients
in the study group (40 ± 4.9 years old) were younger than the controls
(54 ± 8.6 years old).
The frequency of analyzed genotypes at each locus was compatible with Hardy–
Weinberg equilibrium. Only the frequency of the MMP1 alleles deviated
significantly from the expected value (p = 0.0004).
Because we obtained a very low frequency of genotypes in our study, we decided
to compare the polymorphic allele carrier state between analyzed groups (Table 3).
Univariate analyses show that the following factors meet the inclusion criteria for
multivariate logistic regression: gender, hypertension, hypercholesterolemia, family
history of first-degree relatives, and the four polymorphisms FVII (–323 A1/A2),
PECAM1 373 C/G (L125 V), PECAM1 G1688A (Ser563Asn), and MMP9 (–1562
C/T). The multivariate analysis (Table 4) shows that among young patients, a higher
risk of myocardial infarction was related to gender, hypertension, hypercholester-
olemia, myocardial infarction in first-degree relatives, carrier state of allele G of
PECAM1 373C/G, interaction between the carrier state of allele T of MMP9
-1562C/T and hypertension, interaction between the carrier state of allele A of
PECAM1 G1688A and first-degree relatives. A decrease in risk was related to the
carrier state of the A2 allele of FVII A1/A2.
Other univariate analyses show that significant coronary stenosis (above 75%)
was related to seven polymorphisms: C667T MTHFR, K469E ICAM1, –1607 1G/
2G MMP1, –1612 5A/6A MMP3, K167N LOX-1, –675 4G/5G PAI, and IVS7 FVII
(Table 5).
We also analyzed the impact of clinical risk factors on the number of coronary
arteries with stenosis [ 75% (Table 6). Only three factors were associated with a
higher number ([ 3) of such arteries: a high level of low-density lipoprotein
([ 135 mg/dl; p = 0.00003), a high level of triglycerides ([ 155 mg/dl; p = 0.02),
and smoking (p = 0.07).
Table 6 Association of clinical factors, minor alleles, and coronary artery stenosis
Allele OR 95% CI
Carrier T MTHFR (C677T) 1.260 1.001 1.618
Carrier 6A/6A MMP3 (–1612 5A/6A) 1.568 1.201 2.048
Carrier 6A/6A MMP3 (–1612 5A/6A) and smoking habit 1.378 1.065 1.782
Multivariate analysis based on Tables 4 and 5
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Discussion
The aim of this study was to investigate 17 functional polymorphisms in genes
related to atherosclerosis to elucidate their impact on the occurrence of myocardial
infarction in Caucasians under 45 years of age. We performed univariate analyses of
the chosen polymorphisms and risk factors, and statistically significant data were
found in multivariate logistic regression analyses.
We found that carriers of allele T of the MTHFR C677T polymorphism have a
higher risk of atherosclerosis than noncarriers. Patients with this allele have
statistically significant (p = 0.03) critical stenosis ([ 75%) in a minimum of three
coronary arteries. The C677T (variant T) mutation reduces the specific activity of
MTHFR, increases its thermolability, and has been reported to induce hyperhom-
ocysteinemia. A high level of homocysteine is considered an important risk factor
for cardio- and cerebrovascular diseases (Dikmen et al. 2006). Our results are in
agreement with the study of Kluijtmans and Whitehead (2001), who found that
carriers of the CT genotype have a higher risk of atherothrombosis than CC
homozygotes. The role of the MTHFR C677T polymorphism in the development of
coronary artery disease or myocardial infarction was confirmed in two independent
meta-analyses. Xuan et al. (2011) qualified a total of 30 case–control studies
containing 8,140 myocardial infarction cases and 10,522 controls for meta-analysis.
They found that the MTHFR C677T polymorphism was associated with risk of
myocardial infarction in young/middle-aged Caucasians (OR 1.275, 95% CI:
1.077–1.509). The second meta-analysis included 2,981 Chinese Han subjects. In
this population the frequency of the TT genotype was more common among patients
with coronary artery disease than the control group (Li 2012). Regardless of the
results of recent meta-analyses, the role of the C677T polymorphism in the
etiopathology of coronary artery disease and myocardial infarction is still
controversial, and it has not been observed in some populations (Balogh et al.
2012; Iqbal et al. 2005). This discrepancy may be related to differences in genetic
background in the populations studied or to differences in the selection of patients
and healthy controls.
Normal arterial endothelium resists prolonged contact with leukocytes, including
blood monocytes. When endothelial cells undergo inflammatory activation, they
increase their expression of various leukocyte adhesion molecules, such as selectin
E, ICAM1, VCAM, and PECAM1 (Libby 2002). The expression of adhesion
molecules is additionally stimulated by elevating the level of LOX-1 molecules on
the surface of the endothelium (Dunn et al. 2008). In this study we report that
polymorphisms of some molecules expressed on the surface of the endothelium
[selectin E (Ser128Arg), ICAM1 (K469E), and LOX-1 (G501C)] are not associated
with myocardial infarction or formation of atherosclerotic lesions. Only two
polymorphisms that code adhesion molecules had a positive effect on the pathology
of myocardial infarction among our young patients. The multivariate analysis shows
that the risk of myocardial infarction among carriers of variant G (125 Val) of the
polymorphism (C373G; Leu125Val) PECAM1 was almost 1.6-fold that of CC
homozygotes (OR 1.571, 95% CI: 1.185–2.082). We found that the carriers of allele
A (563Asn; G1688A; Ser563Asn) of the same adhesion molecules (PECAM1) also
238 Biochem Genet (2013) 51:230–242
123
had a higher risk of myocardial infarction if they had a first-degree relative. According
to the literature, these polymorphisms are located in exons 3 and 8 of the extracellular
domain, which is responsible for binding PECAM1 with other molecules (e.g.,
leukocytes). This binding is responsible for the transendothelial migration of
immunological cells, which is necessary for the development of atherosclerosis
(Fang et al. 2005). Our results are in agreement with the study conducted by Yang et al.
(2007), who found that carriers of the AA genotype (Asn563Asn) have a higher risk of
myocardial infarction than GG/GA subjects (OR 2.13; 95% CI: 1.08–4.41). Moreover,
Wenzel et al. (1999) have shown that carriers of alleles A (G1688A) and G (C373G) of
PECAM1 had a higher risk of coronary artery disease than wild homozygotes. The
correlation of these polymorphisms of PECAM1 with coronary artery disease or
myocardial infarction was confirmed by other researchers in Japanese and South
Indian populations (Fang et al. 2005; Sasaoka et al. 2001).
Immunological cells located in the intima (macrophages, T cells, and mast cells)
produce several types of molecules: inflammatory cytokines, metalloproteinases,
coagulation factors, radicals, and vasoactive molecules (Hansson 2005). Metallo-
proteinases belong to a family of endopeptidases that degrade proteins of the
extracellular matrix (e.g., the fibrous cap that covers the lipid-rich core of the
atherosclerotic lesion). This might weaken the fibrous cap and subsequently
destabilize an atherosclerotic lesion (Koenig and Khuseyinova 2007). In this study
we tried to find correlations of three MMP polymorphisms (–1607 1G/2G MMP1;
–1612 5A/6A MMP3; –1562 C/T MMP9) with a higher risk of myocardial
infarction and formation of atherosclerosis plaque. We found that individuals with
the 6A/6A genotype had a greater extent of coronary atherosclerosis than
individuals with other genotypes (OR 1.568, 95% CI: 1.201–2.048). In vitro assays
revealed promoter activity of the 5A allele was twice that of the 6A allele (Zhou
et al. 2004). Therefore, individuals homozygous for the 6A allele should have lower
MMP3 levels in their arterial walls because of reduced gene transcription. Lower
levels of this enzyme might favor the accumulation of extracellular matrix and the
progression of atherosclerosis (Zhou et al. 2004). Beyzade et al. (2003) have shown
that the 6A allele is associated with an increased rate of progression of coronary
atherosclerosis (OR 1.52; p = 0.008). The same observation (that individuals
carrying the 6A/6A genotype may be predisposed to develop atherosclerotic plaques
with significant stenosis) was described by other researchers (Ye 2006; Hirashiki
et al. 2003).
In our study we observed that the carrier state of allele T of the –1562 C/T MMP9
polymorphism was correlated with hypertension and a higher risk of myocardial
infarction. The risk of myocardial infarction among hypertensive carriers of allele T
was almost 1.5-fold that of CC homozygotes, an observation consistent with the
results of Blankenberg et al. (2003). They found that the increased expression of
MMP9, which was related to the carrier state of allele T MMP9, weakened the cap
of the atherosclerotic lesion. The thin layer of the atherosclerotic cap is more prone
to rupture under hypertensive conditions. The meta-analyses conducted by Wang
et al. (2011) demonstrated that carriers of the T allele have a higher risk associated
with increased myocardial infarction susceptibility (OR 1.14, 95% CI: 1.02–1.27;
p = 0.02).
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The exposure of thrombogenic factors released from an atherosclerotic lesion
after its rupture may lead to thrombosis (Thim et al. 2008). In this study we found
that young Caucasian carriers of the A2 allele of the –323A1/A2 FVII polymor-
phism have a decreased risk of myocardial infarction. This result agrees with our
previous study, in which we found that carriers of this allele have a lower risk of
myocardial infarction than noncarriers (OR 0.40, 95% CI: 0.20–0.80) (Sakowicz
et al. 2010a). According to the literature, this polymorphism influences the level of
FVII in blood. The A2 allele decreases the level of factor VII, which may lead to a
lower risk of myocardial infarction (Sakowicz et al. 2010a). Our results agree with
the study by Bozzini et al. (2004), in which male carriers of –323A2 were protected
against myocardial infarction (OR 0.6, 95% CI: 0.39–0.94). This observation is also
consistent with that of Di Castelnuovo et al. (2000).
Controversially, Bernardi et al. (1996) did not report any protective effect of the
–323A2 allele. The same results were observed by Nederhand et al. (2001), who
reported that in an Italian population the A2 allele was present in 11% of patients
with a history of myocardial infarction and in 10.8% of patients with no history of
myocardial infarction.
This study shows that formation of atherosclerotic lesions is strongly correlated
with genetic factors in young Caucasians. We found that the C677T MTHFR and
–1612 5A/6A MMP3 polymorphisms have strong influences on the formation of
atherosclerotic plaque. We observed some correlation among the polymorphisms
studied as well as between polymorphisms and environmental risk factors. Our
study indicates that PECAM1 polymorphisms and the –1562 C/T MMP9 polymor-
phism have a positive effect on (i.e., increase) the risk of myocardial infarction in
subjects under 45 years of age.
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